Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone353-1609-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.16 billion
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
Shire (NASDAQ:SHPG) Frequently Asked Questions
What is Shire's stock symbol?
Shire trades on the NASDAQ under the ticker symbol "SHPG."
How were Shire's earnings last quarter?
Shire PLC (NASDAQ:SHPG) released its earnings results on Thursday, April, 26th. The biopharmaceutical company reported $3.86 EPS for the quarter, topping analysts' consensus estimates of $3.58 by $0.28. The biopharmaceutical company earned $3.77 billion during the quarter. Shire had a net margin of 30.63% and a return on equity of 12.70%. The firm's revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm earned $3.63 EPS. View Shire's Earnings History.
Has Shire been receiving favorable news coverage?
News headlines about SHPG stock have been trending negative this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Shire earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the immediate future. View News Stories for Shire.
Who are some of Shire's key competitors?
Some companies that are related to Shire include Novartis (NVS), Merck & Co., Inc. (MRK), Pfizer (PFE), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AbbVie (ABBV), Eli Lilly And Co (LLY), AstraZeneca (AZN), Sanofi (SNY), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG), Bayer (BAYRY) and Zoetis (ZTS).
What other stocks do shareholders of Shire own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Shire investors own include Gilead Sciences (GILD), Celgene (CELG), Intel (INTC), Merck & Co., Inc. (MRK), Cisco Systems (CSCO), Starbucks (SBUX), Walt Disney (DIS), Johnson & Johnson (JNJ), Pfizer (PFE) and Exxon Mobil (XOM).
Who are Shire's key executives?
Shire's management team includes the folowing people:
- Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
- Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
- Gisele Dion, Chief Accounting Officer
- Mr. Matthew Walker, Head of Technical Operations (Age 54)
- Dr. Andreas Busch Ph.D., Head of R&D and Chief Scientific Officer (Age 55)
What is Shire's stock price today?
One share of SHPG stock can currently be purchased for approximately $179.20.
How big of a company is Shire?
Shire has a market capitalization of $54.71 billion and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $15.15 on an earnings per share basis. View Additional Information About Shire.
What is Shire's official website?
How can I contact Shire?
Shire's mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The biopharmaceutical company can be reached via phone at 353-1609-6000 or via email at [email protected]
MarketBeat Community Rating for Shire (NASDAQ SHPG)
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHPG will underperform the S&P 500 over the long term. You may vote once every thirty days.
